July 2024 – Page 239 – Get News Story

B-Cell Lymphoma Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

“B-Cell Lymphoma Pipeline”

(Albany, United States) As per DelveInsight’s assessment, globally, B-Cell Lymphoma pipeline constitutes 160+ key companies continuously working towards developing 170+ B-Cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“B-Cell Lymphoma Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-Cell Lymphoma Market.

The B-Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ B-Cell Lymphoma Pipeline Analysis

Some of the key takeaways from the B-Cell Lymphoma Pipeline Report:

B-Cell Lymphoma Companies across the globe are diligently working toward developing novel B-Cell Lymphoma treatment therapies with a considerable amount of success over the years.
B-Cell Lymphoma companies working in the treatment market are Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Guangzhou Lupeng Pharmaceutical, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Nanjing Legend Biotech Co.and others, are developing therapies for the B-Cell Lymphoma treatment
Emerging B-Cell Lymphoma therapies such as Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-B-Cell Lymphoma Inhibitor (LOX Inhibitor), and others are expected to have a significant impact on the B-Cell Lymphoma market in the coming years.

B-Cell Lymphoma Overview

B-cell lymphoma is a type of non-Hodgkin lymphoma that originates in the B-cells. It is the most common type of lymphoma and about 85% of all lymphomas in the United States are B-cell. Common symptoms associated with lymphoma include painless enlargement of one or more lymph node areas, fever, night sweats, and weight loss. Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma. DLBCL typically affects older people and accounts for one out of three cases of non-Hodgkin lymphoma. This type of B-cell lymphoma usually begins as a mass in a lymph node, but can also form in particular sites such as bone, intestine, the spinal cord or brain. Standard treatment for DLBCL generally involves months of conventional chemotherapy, and overall cure rates in the last 15 years have been about 70%. Diffuse large B-cell lymphoma has long been treated as a single disease, but it is now categorized into many different subtypes based on their molecular features. There are two large subtypes: germinal center b-cell (GCB) and activated b-cell (ABC). B-cell lymphomas arise from different stages of differentiation of B-cells and constitute a broad spectrum, extending from small- to large-cell types, and from low to high grades of clinical behavior.

Get a Free Sample PDF Report to know more about B-Cell Lymphoma Pipeline Therapeutic Assessment @ B-Cell Lymphoma Treatment Market

B-Cell Lymphoma Route of Administration

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
intravenous
Subcutaneous
Topical

B-Cell Lymphoma Molecule Type

B-Cell Lymphoma Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

B-Cell Lymphoma Pipeline Therapeutics Assessment

B-Cell Lymphoma Assessment by Product Type
B-Cell Lymphoma By Stage and Product Type
B-Cell Lymphoma Assessment by Route of Administration
B-Cell Lymphoma By Stage and Route of Administration
B-Cell Lymphoma Assessment by Molecule Type
B-Cell Lymphoma by Stage and Molecule Type

DelveInsight’s B-Cell Lymphoma Report covers around 170+ products under different phases of clinical development like-

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further B-Cell Lymphoma product details are provided in the report. Download the B-Cell Lymphoma pipeline report to learn more about the emerging B-Cell Lymphoma therapies @ B-Cell Lymphoma Therapeutics Assessment

B-Cell Lymphoma Pipeline Analysis:

The B-Cell Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma Treatment.
B-Cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
B-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Lymphoma market.

Download Sample PDF Report to know more about B-Cell Lymphoma drugs and therapies @ B-Cell Lymphoma Clinical Trials and FDA Approvals

Scope of B-Cell Lymphoma Pipeline Drug Insight

Coverage: Global
Key B-Cell Lymphoma Companies: Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Guangzhou Lupeng Pharmaceutical, TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Nanjing Legend Biotech Co.and others.
Key B-Cell Lymphoma Therapies: Epeleuton, Tipelukast, TA 270, MW 001, PTC 857, Baicalein, VLX 1005, Research programme: 5-B-Cell Lymphoma Inhibitor (LOX Inhibitor), and others.
B-Cell Lymphoma Therapeutic Assessment: B-Cell Lymphoma current marketed and B-Cell Lymphoma emerging therapies
B-Cell Lymphoma Market Dynamics: B-Cell Lymphoma market drivers and B-Cell Lymphoma market barriers

Request for Sample PDF Report for B-Cell Lymphoma Pipeline Assessment and clinical trials @ B-Cell Lymphoma therapies and drugs

Table of Contents

1. B-Cell Lymphoma Report Introduction

2. B-Cell Lymphoma Executive Summary

3. B-Cell Lymphoma Overview

4. B-Cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. B-Cell Lymphoma Pipeline Therapeutics

6. B-Cell Lymphoma Late Stage Products (Phase II/III)

7. B-Cell Lymphoma Mid Stage Products (Phase II)

8. B-Cell Lymphoma Early Stage Products (Phase I)

9. B-Cell Lymphoma Preclinical Stage Products

10. B-Cell Lymphoma Therapeutics Assessment

11. B-Cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. B-Cell Lymphoma Companies

14. B-Cell Lymphoma Key Products

15. B-Cell Lymphoma Unmet Needs

16 . B-Cell Lymphoma Market Drivers and Barriers

17. B-Cell Lymphoma Future Perspectives and Conclusion

18. B-Cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Lymphoma Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Postoperative Pain Treatment Market 2032: FDA Approvals, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight

“Postoperative Pain Market”

Postoperative Pain Companies are Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.

DelveInsight’s “Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Postoperative Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Postoperative Pain market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Postoperative Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Postoperative Pain market.

Request for a Free Sample Report @ Postoperative Pain Market Forecast

Some facts of the Postoperative Pain Market Report are:

In 2022, Postoperative Pain market size was highest in the US among the 7MM, accounting for approximately USD 2,080 million, which is further expected to increase by 2032.
Leading Postoperative Pain companies working in the market are Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.
Key Postoperative Pain Therapies expected to launch in the market are TLC590, TPU-006 (Dexmedetomidine Transdermal System [DMTS]), Libvatrep (SAF312), Vocacapsaicin (CA-008), Nepafenac PPDS/Nepafenac Evolute, F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib), SURF-201 (betamethasone 0.2% in KLARITY vehicle), SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%), QUTENZA (8% capsaicin), VX-548, APP13007 (clobetasol propionate ophthalmic nanosuspension), OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%), NTM-001 (ketorolac premixed bag), CL-108 (hydrocodone/acetaminophen/promethazine or HYDEXOR), and others.

Postoperative Pain Overview

Postoperative Pain is an anticipated and temporary increase in background pain following surgical procedures. It is a type of pain that typically lasts less than a few days to months or pain directly related to soft tissue damage such as a sprained ankle or a paper cut. The pain is of short duration, but it gradually resolves as the injured tissues heal.

Proper diagnosis of the type and intensity of pain is crucial for an adequate and targeted treatment of acute pain. Specific evaluation of pain includes the location of the pain and its radiation, quality of the pain (dull, sharp, throbbing, shooting, burning, etc.), duration of the pain (constant, intermittent, paroxysmal), causative factors (movement, sitting position, cough, etc., the intensity of the pain at rest or during movement), accompanying symptoms, quality of sleep, assessment of the patient’s expectations, personal approach to pain, stress, and pain coping strategies, analgesic therapy preferences.

Learn more about Postoperative Pain treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Postoperative Pain Treatment Market

Postoperative Pain Market

The Postoperative Pain market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Postoperative Pain market trends by analyzing the impact of current Postoperative Pain therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Postoperative Pain market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Postoperative Pain market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Postoperative Pain market in 7MM is expected to witness a major change in the study period 2019-2032.

Postoperative Pain Epidemiology

The Postoperative Pain epidemiology section provides insights into the historical and current Postoperative Pain patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Postoperative Pain market report also provides the diagnosed patient pool, trends, and assumptions.

The total number of surgical procedures in the US was around 58,190,000 in 2022.
DelveInsight estimates that there were around 9,765,000, 4,875,000, and 3,458,000 cases of mild, moderate, and severe cases of Postoperative Pain, respectively, in EU4 and the UK in 2022. The cases are projected to increase during the forecast period.

Explore more about Postoperative Pain Epidemiology @ Postoperative Pain Prevalence

Postoperative Pain Drugs Uptake

This section focuses on the uptake rate of the potential Postoperative Pain drugs recently launched in the Postoperative Pain market or expected to be launched in 2019-2032. The analysis covers the Postoperative Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Postoperative Pain Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Postoperative Pain market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Postoperative Pain Pipeline Development Activities

The Postoperative Pain report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Postoperative Pain key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Postoperative Pain pipeline development activities @ Postoperative Pain Therapies and Drugs

Postoperative Pain Therapeutics Assessment

Major key companies are working proactively in the Postoperative Pain Therapeutics market to develop novel therapies which will drive the Postoperative Pain treatment markets in the upcoming years are Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others.

Request for Sample Report @ Postoperative Pain Clinical Trials and FDA Approvals

Postoperative Pain Report Key Insights

1. Postoperative Pain Patient Population

2. Postoperative Pain Market Size and Trends

3. Key Cross Competition in the Postoperative Pain Market

4. Postoperative Pain Market Dynamics (Key Drivers and Barriers)

5. Postoperative Pain Market Opportunities

6. Postoperative Pain Therapeutic Approaches

7. Postoperative Pain Pipeline Analysis

8. Postoperative Pain Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Postoperative Pain Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Postoperative Pain Competitive Intelligence Analysis

4. Postoperative Pain Market Overview at a Glance

5. Postoperative Pain Disease Background and Overview

6. Postoperative Pain Patient Journey

7. Postoperative Pain Epidemiology and Patient Population

8. Postoperative Pain Treatment Algorithm, Current Treatment, and Medical Practices

9. Postoperative Pain Unmet Needs

10. Key Endpoints of Postoperative Pain Treatment

11. Postoperative Pain Marketed Products

12. Postoperative Pain Emerging Therapies

13. Postoperative Pain Seven Major Market Analysis

14. Attribute Analysis

15. Postoperative Pain Market Outlook (7 major markets)

16. Postoperative Pain Access and Reimbursement Overview

17. KOL Views on the Postoperative Pain Market

18. Postoperative Pain Market Drivers

19. Postoperative Pain Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postoperative Pain Treatment Market 2032: FDA Approvals, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight

Lion Heart Film Works is Bringing Stephen Crane’s Iconic Novel “The Red Badge of Courage” to Life

Lion Heart Film Works has launched a new Kickstarter campaign with the aim of continuing funding the cinematic adaptation of Stephen Crane’s renowned novel “The Red Badge of Courage.” Kevin R. Hershberger, an Emmy-nominated director, is leading this project and is committed to crafting a compelling and realistic American Civil War film.

Experts Speak

In the words of Stanley Wertheim, a renowned Crane scholar, “The Red Badge of Courage” is “unquestionably the most realistic novel about the American Civil War” and is a literary masterpiece. The aim of this cinematic adaptation is to commemorate the experiences of Civil War warriors and provide an unparalleled degree of historical realism while properly recreating the novel’s profound study of terror, bravery, and personal growth.

A Campaign for All Ages

Hershberger aims to involve the audience as investors to ensure the film’s production remains uncompromised and true to its source material. He recognizes the risks but is fully committed to completing the film within the next year. The funds raised will directly impact the number of shooting days, allowing for a more thorough and detailed production process.

Support the Campaign

Supporting this campaign means contributing to a once-in-a-generation motion picture that will stand the test of time. People who have long enjoyed Hershberger’s previous historical projects are bound to love this one. Project backers can help create a film that everyone can be proud of- a film that excites future generations of Civil War enthusiasts.

Become a Backer

Starting at the $45 level, backers will be among the first to see the final film and gain exclusive access to weekly video updates on Kickstarter featuring edited completed scenes. Backers will receive frequent updates on the production’s progress, including behind-the-scenes content and shoot dates. Becoming a backer means becoming an integral part of the production.

Realizing a Long-Held Dream

Bringing “The Red Badge of Courage” to the screen has been a long-term dream for Hershberger. After completing his first film, “Wicked Spring,” in 2003, he wrote the script for this project but initially found it too ambitious. With over 20 years in the industry, directing nearly 100 hours of prime-time television, and armed with the latest CGI and digital film technology, Hershberger is ready to realize this dream without compromise.

Shooting Commences in Virginia

Recently, the cast and crew gathered at locations west of Richmond, Virginia, to begin filming. They completed 15 scenes and 38 pages of the script, coinciding with the dates and events depicted in Crane’s novel from 1863. The film will use a handheld, intimate viewpoint, presenting the story from the perspective of Henry Fleming and his comrades.

Meet the Talent

The role of Henry Fleming, “The Youth,” is played by Aidan M. Close, an accomplished actor with a background in Shakespeare and notable roles in new plays and major tours. The production will be handled by Kevin R. Hershberger, an Emmy-nominated filmmaker who has won over 70 national and international awards. Hershberger also has a rich background in military history and filmmaking, having worked on numerous museum projects, series, docu-dramas, and features for national and international distribution.

Support The Kickstarter campaign at https://www.kickstarter.com/projects/lionheartfilmworks/the-red-badge-of-courage-motion-picture

Get the latest updates about the movie at: http://www.redbadgemovie.com

Please like & follow at: https://www.facebook.com/lionheartfilmworks/

Watch “The Red Badge of Courage” (2026) Teaser Trailer” on YouTube: https://www.youtube.com/watch?v=fK4NbOlR98g

Media Contact
Company Name: Lion Heart Film Works
Contact Person: Kevin R. Hershberger
Email: Send Email
Phone: (804) 683-0937
City: Richmond
State: Virginia
Country: United States
Website: www.lionheart-filmworks.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lion Heart Film Works is Bringing Stephen Crane’s Iconic Novel \”The Red Badge of Courage\” to Life

Bookbinding Materials Market Size, Opportunities, Top Companies Analysis, Growth, Trends, Key Segments, and Forecast to 2028

“Browse 157 market data Tables and 61 Figures spread through 222 Pages and in-depth TOC on “Bookbinding Materials Market””

The bookbinding materials market is expanding, driven by the demand for high-quality, durable, and aesthetically pleasing book covers. Major markets include North America, Europe, and Asia-Pacific, with key materials being leather, cloth, and paper.

The bookbinding materials market is projected to grow from USD 8.3 billion in 2023 to USD 9.5 billion by 2028, at a CAGR of 2.3% between 2023 and 2028. The driving factors for bookbinding materials include the growing publishing industry, expanding education sectors, and Increasing demand for printed materials. As the publishing industry continues to flourish globally, there is a heightened need for durable and visually appealing books and publications, thereby propelling the demand for high-quality bookbinding materials. Additionally, the expanding education sector, characterized by the rise in educational institutions and literacy rates, is fueling the requirement for a wide range of educational materials, including textbooks, workbooks, and reference materials, driving the consumption of bookbinding materials further. Moreover, the persistent demand for printed materials, such as magazines, catalogs, and newspapers, owing to the tactile and immersive reading experience they offer, is contributing to the continuous growth of the bookbinding materials market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137402686

The major players operating in the bookbinding materials market include Henkel AG (Germany), H.B. Fuller (US), Arkema (US), The Dow Chemical Company (US), UPM Global (Finland), and others.

Henkel AG: Henkel AG & Co KGaA is a global manufacturer and distributor of a diverse range of consumer and industrial goods. Their product line includes adhesives, sealants, coatings, care products, and various cleaning agents. Henkel markets these products under well-known brand names such as Persil, Purex, Pril, Dial, and Schwarzkopf, among others. The company caters to multiple industries, serving manufacturers in the fields of books and magazines, computers, furniture, textiles, and packaging. Headquartered in Dusseldorf, Germany, Henkel operates on a global scale, conducting business operations worldwide.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137402686

In June 2022, Henkel expanded its production capabilities in Mexico by opening a new state-of-the-art plant for hot-melt adhesives in Guadalupe, Nuevo Leon. The new facility has been designed primarily for manufacturing pressure-sensitive and non-pressure-sensitive hot melts under the leading Technomelt brand.

H.B. Fuller: H.B. Fuller Co is a renowned developer, producer, and distributor of adhesives, sealants, and specialty chemical solutions. The company’s extensive product range serves various sectors, including residential construction, electronics, medical, transportation, packaging, and more. With a strong focus on customer satisfaction, H.B. Fuller provides tailored technical support and customized products to meet specific industry requirements. Its market outreach spans across North America, Europe, Latin America, Asia-Pacific, India, the Middle East, and Africa, with its headquarters situated in St. Paul, Minnesota, in the United States.

In 2017, H.B. Fuller announced the opening of a new office in Dubai. This new office is expected to support the company’s increasing base of customers in the Middle East and also offer manufacturers an alternative source for adhesives & sealants in the region.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137402686

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/bookbinding-materials-market-137402686.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bookbinding Materials Market Size, Opportunities, Top Companies Analysis, Growth, Trends, Key Segments, and Forecast to 2028

KumariDevi Announces Divine Feminine Activation Along the Nile Egypt Sacred Tour

Albuquerque, New Mexico – KumariDevi, Founder of the Kumara Institute, author, and spiritual meditation teacher, is thrilled to unveil the highly anticipated Divine Feminine Activation Along the Nile Egypt Sacred Tour. This immersive fourteen-day retreat is February 15-28, 2025, invites women to embark on a transformative spiritual journey amidst the captivating landscapes of Egypt. Journeying through Egypt participants will immerse themselves into the mysteries of Ancient Egypt through a powerful retreat style and sightseeing tour.The ancient echoes of Egypt call to the soul, inviting individuals to reclaim their wholeness.

Egypt Sacred Tour boasts five-star accommodations in Aswan, Cairo, and Luxor, with seamless round-trip airfare from Cairo to Luxor provided for all participants. Exclusive first-class transportation services will ensure a comfortable and stress-free exploration of Egypt.

in the meditative ambiance of the majestic pyramids, fostering moments of inner peace. The itinerary includes sailing the Nile on a traditional Felucca, visits to the ancient temples of Luxor, Abydos, and Karnak, offering a gateway to unravel the mysteries of ancient wisdom and spirituality.

Divine Feminine Activation Along the Nile Sacred Tour is curated to guide women in healing fear and doubt, fostering accelerated personal growth. From the timeless pyramids of Giza to the vibrant city of Luxor, participants will delve into the enigmatic tapestry of ancient Egypt, gaining profound insights that promise to positively influence their lives.

Beyond spiritual and meditative experiences, participants will have the opportunity to indulge in camel rides, explore unique marketplaces, and partake in enchanting evening walks to the awe-inspiring Luxor Temples.

For those seeking an unparalleled journey of self-discovery and spiritual enlightenment. Join us on this profound exploration of mind, body, and spirit, as we unlock the wisdom of ancient Egypt together.

Meet KumariDevi: A Visionary Guide with Over Three Decades of Transformative Leadership, KumariDevi stands as a revered retreat leader with a rich legacy of over thirty-years, leaving an indelible mark on the lives of countless individuals worldwide through her profound spiritual and meditation retreats.

KumariDevi has devoted her life to empowering individuals on their unique paths of self-discovery and spiritual evolution. Her extraordinary ability to transcend the ordinary boundaries of consciousness enables her to craft impactful and transformative experiences for her students, making her a sought-after guide in the realm of personal and spiritual growth.

https://www.kumarainstitute.com/egypt-spiritual-tour

Media Contact
Company Name: Kumara Institute
Contact Person: KumariDevi (aka Paula Muran)
Email: Send Email
Phone: 505 681-3509
Country: United States
Website: https://www.kumarainstitute.com/egypt-spiritual-tour

Laser Capture Microdissection Market worth $306 million by 2029 | MarketsandMarkets™

“Laser Capture Microdissection Market in terms of revenue was estimated to be worth $184 million in 2024 and is poised to reach $306 million by 2029, growing at a CAGR of 10.6% from 2024 to 2029 according to a new report by MarketsandMarkets™”

Browse 139 market data Tables and 40 Figures spread through 193 Pages and in-depth TOC on “Laser Capture Microdissection Market by Product (Instruments, Consumables, Software, Services), System Type (Ultraviolet, Infrared, Immunofluorescence), Application (R&D (Molecular Biology, Cell Biology, Forensics), Diagnostics) – Global Forecast to 2029

Laser Capture Microdissection Market in terms of revenue was estimated to be worth $184 million in 2024 and is poised to reach $306 million by 2029, growing at a CAGR of 10.6% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth of this market is driven by increasing demand of laser capture microdissection in cancer research, collaborations between academic institutions, research organizations, and industry players to develop innovative LCM technologies. Additionally, continuous advancements in laser technology, microscopy, and automation have led to improved precision, efficiency, and ease of use of LCM systems.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140404059

The consumables segment accounted for the largest share, by product in the laser capture microdissection market in 2023.

By product, the laser capture microdissection market has been further categorized as instruments, consumables, software and services. The consumables segment held the largest share of the global laser capture microdissection market in 2023. This can be attributed to increasing adoption of LCM technology across various research fields, advancements in sample preparation techniques, and the rising demand for personalized medicine. Furthermore, support from government agencies and funding organizations for research initiatives in areas such as cancer, neuroscience, and precision medicine provides financial resources for the procurement of LCM consumables. Government funding drives research activities and accelerates the adoption of LCM technology, thereby stimulating the demand for consumables.

The research and development segment accounted for the largest share of the application segment in the laser capture microdissection market in 2023.

Based on application, the global laser capture microdissection market has been segmented into research & development, diagnostics, and other applications. The research & development segment held the largest market share in 2023. The large share of this segment can be attributed to the use of laser capture microdissection for gene expression analysis has lent itself to a diverse set of research areas and applications, including cancer biology, cell biology, neurobiology, pathology, neuroscience, and developmental biology.

The North America region catered the largest share of the laser capture microdissection market in 2023.

The laser capture microdissection market in North America has experienced significant growth in recent years, showcasing a robust expansion trajectory, owing to large pharmaceutical & biopharmaceutical industry in the region, the rising R&D expenditure, stringent regulations, and the presence of major providers of laser capture microdissection products in the US and Canada. Additionally, growth of the North American laser capture microdissection market is driven by significant factors such as a multitude of ongoing cancer research and clinical trials, the expansion of the biosimilars and generics sector, and the increasing adoption of outsourcing preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=140404059

Laser Capture Microdissection Market Dynamics:

Drivers:

1. Increase in R&D funding

Restraints:

1. Requirement of high degree of technical expertise

Opportunities:

1. Integration with omics technologies

Challenge:

1. Time-consuming sample preparation process

Key Market Players of Laser Capture Microdissection Industry:

Key players in the laser capture microdissection market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Carl Zeiss AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Standard BioTools (US), JSR Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Molecular Machines & Industries GmbH (Germany), Ocimum Biosolutions (US), Theralink Technologies, Inc. (US), 3DHISTECH, Ltd. (Hungary), Creative Biolabs (US), DeNova Sciences (Singapore), Laxco, Inc. (US), CaresBio Laboratory LLC (US), VitroVivo Biotech (US), AnaPath Services GmbH (Switzerland), Gnome Diagnostics & Gnome Sciences (US), Monasterium Laboratory (Germany), Independent Forensics (US), Norgen Biotek Corp. (Canada), Creative Bioarray (US), and Epistem Ltd. (UK).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 60% and Demand Side 40%
By Designation: C-level – 50%, D-level – 20%, and Others – 30%
By Region: North America -40%, Europe -40%, and Asia-Pacific -20%

Recent Developments of Laser Capture Microdissection Industry:

In August 2023, Danaher Corporation (US) acquired Abcam plc (UK), a leading supplier of protein consumables. Abcam is to operate as a standalone operating company and brand within Danaher’s Life Sciences segment, furthering Danaher’s strategy to help map complex diseases and accelerate the drug discovery process using Danaher’s technology.
In March 2023, Crown Bioscience International (US), a JSR Life Sciences Company, acquired a 100.0% stake in Indivumed Services GmbH& Co. KG (Germany) to further accelerate drug discovery and create solutions to meet customer needs by bringing a variety of synergistic service platforms to Crown Bioscience’s drug discovery and development services.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=140404059

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/laser-capture-microdissection-market-140404059.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Laser Capture Microdissection Market worth $306 million by 2029 | MarketsandMarkets™

Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics

DelveInsight’s, “Advanced Merkel cell carcinoma Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Advanced Merkel cell carcinoma pipeline landscape. It covers the Advanced Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Merkel Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Merkel Cell Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Merkel Cell Carcinoma Pipeline Outlook

Key Takeaways from the Advanced Merkel Cell Carcinoma Pipeline Report

June 2024:- Ocellaris Pharma, Inc.- A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers. This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
DelveInsight’s Advanced Merkel Cell Carcinoma Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Advanced Merkel Cell Carcinoma treatment.
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.
Promising Advanced Merkel Cell Carcinoma Therapies such as Avelumab, BT-001, GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, OC-001, and others.

Stay informed about the cutting-edge advancements in Advanced Merkel Cell Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Merkel Cell Carcinoma Clinical Trials Assessment

Advanced Merkel cell carcinoma Emerging Drugs Profile

Tidutamab: Xencor, Inc.

Tidutamab (previously XmAb18087) is a bispecific antibody that engages the immune system against tumors by binding to somatostatin receptor 2 (SSTR2) and CD3. Xencor’s XmAb® Bispecific Fc Domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on tidutamab. Engagement of CD3 by tidutamab activates T cells for highly potent and targeted killing of SSTR2-expressing tumor cells.

Cabozantinib: Exelixis

In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda Pharmaceutical Company Limited for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Advanced Merkel cell carcinoma.

Learn more about Advanced Merkel Cell Carcinoma Drugs Opportunities in our groundbreaking Advanced Merkel Cell Carcinoma Research and development projects @ Advanced Merkel Cell Carcinoma Unmet Needs

Advanced Merkel cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
intravenous
Subcutaneous
Topical.

Advanced Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Discover the latest advancements in Advanced Merkel Cell Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Advanced Merkel Cell Carcinoma Pipeline Report

Coverage- Global
Advanced Merkel Cell Carcinoma Companies- Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics, ImaginAb, Inc., BioInvent International AB, Ocellaris Pharma, Inc., Sotio a.s., Morphogenesis, Inc., Checkpoint Therapeutics, Inc., and others.
Advanced Merkel Cell Carcinoma Therapies- Avelumab, BT-001, GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, OC-001, and others.
Advanced Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Advanced Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Merkel Cell Carcinoma Pipeline on our website @ Advanced Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

Introduction
Executive Summary
Advanced Merkel cell carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Advanced Merkel cell carcinoma – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Cabozantinib: Exelixis
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
IFx-Hu2.0: Morphogenesis
Drug profiles in the detailed report…..
Inactive Products
Advanced Merkel cell carcinoma Key Companies
Advanced Merkel cell carcinoma Key Products
Advanced Merkel cell carcinoma- Unmet Needs
Advanced Merkel cell carcinoma- Market Drivers and Barriers
Advanced Merkel cell carcinoma- Future Perspectives and Conclusion
Advanced Merkel cell carcinoma Analyst Views
Advanced Merkel cell carcinoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Merkel Cell Carcinoma Pipeline 2024 | Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, Inc., Exelixis, Bristol-Myers Squibb, bluebird bio, Affini-T Therapeutics

Gene Expression Analysis Market worth $6.2 billion by 2029 | MarketsandMarkets™

“The North American region is observing rising investments in the field of drug discovery & development. Moreover, the need for advanced therapies due to the rising rate of chronic diseases such as cancer has contributed to the growth of the gene expression analysis market.”

Browse 436 market data Tables and 54 Figures spread through 369 Pages and in-depth TOC on “Gene Expression Analysis Market by Product (Reagents, Enzymes, kits, DNA Chips, PCR, NGS, DNA Microarray), Service (RNA Sequencing, Bioinformatics), Application (Drug discovery & development, clinical diagnostics), End User – Global Forecast to 2029

Gene Expression Analysis Market in terms of revenue was estimated to be worth $4.2 billion in 2024 and is poised to reach $6.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The gene expression analysis market is experiencing significant growth due to several key factors. Firstly, the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is driving the demand for advanced diagnostic and therapeutic solutions. Gene expression analysis plays a crucial role in understanding the genetic basis of these diseases, enabling personalized medicine approaches for more effective treatments. However, the high cost of instruments & consumables and concerns associated with data privacy and security are expected to restrain the market growth during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156613968

The assays & kits segment accounted for the largest share of reagents & consumables in the gene expression analysis market in 2023.

By reagents & consumables, the gene expression analysis market has been further categorized into assays & kits, enzymes, DNA chips, and others. Assays & kits accounted for the largest share of the gene expression analysis market in 2023. The increasing adoption of high-throughput technologies such as next-generation sequencing (NGS) and microarray analysis has boosted the demand for assays and kits. These technologies generate large amounts of data, and assays and kits help in streamlining the workflow, from sample preparation to data analysis.

The drug discovery & development application segment is expected to grow at a higher rate during the forecast period.

Based on technology, the gene expression analysis market has been segmented into drug discovery & development, clinical diagnostics, and other applications. In 2023, the drug discovery & development segment accounted for the largest share of the gene expression analysis market and is expected to grow at a higher growth rate during the forecast period of 2024-2029. The share share of drug discovery & development application is attributed to gene expression analysis is instrumental in the preclinical and clinical stages of drug development. In preclinical studies, researchers use gene expression profiling to assess the efficacy and safety of potential drug candidates. This helps in selecting the most promising candidates for further development, reducing the time and cost associated with drug discovery.

The pharmaceutical & biotechnology companies segment accounted for the largest share of the end user segment in the gene expression analysis market in 2023.

Based on end user, the gene expression analysis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the gene expression analysis market. As the pharmaceutical & biotechnology companies heavily rely on understanding how genes are expressed in various disease states to identify potential drug targets. Gene expression analysis helps in pinpointing genes that are upregulated or downregulated in diseases, providing valuable insights into disease mechanisms and potential therapeutic interventions.

The North America region accounted for the largest share of the gene expression analysis market in 2023.

The gene expression analysis market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North American region is observing rising investments in the field of drug discovery & development. Moreover, the need for advanced therapies due to the rising rate of chronic diseases such as cancer has contributed to the growth of the gene expression analysis market. The supportive government regulations in North America for the development of mAbs and biosimilars also contribute to market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=156613968

Gene Expression Analysis Market Dynamics:

Drivers:

1. Advancements in gene editing technologies

2. Increasing funding initiatives for genomic research

3. Growing preference for therapeutic applications

4. Declining costs of sequencing technologies

Restraints:

1. High cost of instruments & consumables

2. Concerns associated with data privacy and security

Opportunities:

1. High growth potential across non-clinical applications

2. Machine learning and AI

3. Growing focus on single-cell analysis

Challenge:

1. Extensive timelines for product approval

2. Data interpretation challenges

Key Market Players of Gene Expression Analysis Industry:

Key players in the gene expression analysis market are Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories Inc. (US), Illumina Inc (US), QIAGEN (Netherlands), F. Hoffmann-La Roche (Switzerland), Revvity (US), PacBio (US), Agilent Technologies Inc (US), Oxford Gene Technology IP Limited (UK), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc (Japan), 10x Genomics (US), Zymo Research Corporation (US), Twist Bioscience (US), Promega Corporation (US), LGC Limited (UK), CD Genomics (US), NanoString Technologies Inc. (US), BioSpyder, Inc (US), Integrated DNA Technologies, Inc (US) and New England Biolabs (US).

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

Recent Developments of Gene Expression Analysis Industry:

In May 2023, Thermo Fisher Scientific and Pfizer collaborated to expand localized access to Next-generation Sequencing-based testing for cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia.
In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics to expand its capabilities by inculcating a new generation of rapid PCR systems into its product portfolio.
In April 2022, Illumina established a new state-of-the-art facility solution center in São Paulo, Brazil, to expand global access to genomics in Latin America. Illumina’s revenue is majorly generated from markets across North America, Europe, the Middle East, and Africa.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=156613968

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene Expression Analysis Market worth $6.2 billion by 2029 | MarketsandMarkets™

X-Ray Detectors Market worth $4.2 billion by 2029

“prominent players in the X-ray detectors market are Varex Imaging Corporation (US), Thales Group( France), Canon( Japan), Fujifilm Corporation (Japan), Agfa-Gevaert Group (Belgium) and Teledyne Technologies(US), and among others.”

X-Ray Detectors Market in terms of revenue was estimated to be worth $3.1 billion in 2023 and is poised to reach $4.2 billion by 2029, growing at a CAGR of 5.0% from 2023 to 2029 according to a new report by MarketsandMarkets™. The market is experiencing growth driven by increased investments in the enhancement of healthcare facilities and digital imaging technologies. The demand for early diagnosis is on the rise, leading to an expanded scope of clinical applications for X-ray detectors. Additionally, the prevalence of chronic disorders requiring prompt examinations is increasing, compounded by the growing trend of sedentary lifestyles.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7004984

The Flat-panel detectors segment is to register significant growth rate over the forecast period of 2023-2029.

Based on the technology, the global X-Ray Detectors Market is categorized based on technology, including Flat Panel Detectors, Computed Radiography Detectors, Line-Scan Detectors, and Charged Coupled Detectors. The flat-panel detector segment is anticipated to experience the most significant growth rate during the forecast period. Computed Radiography detectors hold the second-largest share in the X-Ray detectors market.

The medical applications segment accounted for the largest share of the x-ray detectors market, by application in 2023.

Based on application, the X-ray detectors market is divided into various segments, including medical applications, dental applications, security/defence applications, veterinary applications, industrial applications, and other applications. In 2024, the medical applications segment held the largest market share and is projected to exhibit the highest CAGR throughout the forecast period. This dominance is attributed to factors such as the increasing incidence of disorders requiring pre-diagnostic screening and notable advancements in medical technology, both contributing significantly to the substantial share in this category.

The Asia Pacific market to register the highest growth in the market during the forecast period

Based on region, Asia Pacific X-Ray Detectors Market is anticipated to register the highest growth from 2023 to 2029. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC. The region is witnessing a consistent rise in the uptake of advanced equipment. Significant growth prospects for key players are being fueled by improvements in healthcare systems and government initiatives focused on the modernization of healthcare infrastructure.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=7004984

X-Ray Detectors Market Dynamics:

Drivers:

Investment to advance healthcare facilities & digital imaging Technologies

Restraints:

High cost of X-ray detectors

Opportunities:

Rising healthcare expenditure across developing countries

Challenge:

Lack of animal awareness in emerging and developing countries

Key Market Players of X-Ray Detectors Industry:

As of 2022, prominent players in the X-ray detectors market are Varex Imaging Corporation (US), Thales Group( France), Canon( Japan), Fujifilm Corporation (Japan), Agfa-Gevaert Group (Belgium) and Teledyne Technologies(US), and among others.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3–16%
By Designation: Director-level– 14%, C-level–10%, and Others–76%
By Region: North America– 40%, Europe– 32%, Asia Pacific–20%, Latin America-5%, Middle East and Africa-3%

Recent Developments of X-Ray Detectors Industry:

In May 2023, Varex Imaging Corporation launched the XRD 3131N digital X-ray detector to cater to the rising demand for expedited and more extensive inspections within the rapidly evolving Electric Vehicle (EV) battery manufacturing sector. This enhances the company’s existing portfolio for the EV battery inspection market.
In July 2022, Canon Inc. launched the CXDI-Elite series of wireless digital radiography (DR2) devices, including the CXDI-720C Wireless sensor unit, to markets outside of Japan. These devices aim to enhance user-friendliness across various imaging scenarios while delivering superior image quality to facilitate more accurate diagnostics.
March 2021, At ECF 2021, the Thales unveiled the Pixium 3040F, featuring enhanced image quality, optimized spatial resolution, increased contrast, and superior sensitivity at lower radiation doses.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=7004984

X-Ray Detectors Market – Key Benefits of Buying the Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall x-ray detectors market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: X-Ray Detectors Market worth $4.2 billion by 2029

Medical Robots Market worth $33.8 billion by 2029

“Prominent players in the medical robots market include Intuitive Surgical, Inc. (US), Stryker Corporation (US), Medtronic Plc (US), Smith & Nephew Plc (UK), Zimmer Biomet Holdings, Inc. (US), Asensus Surgical, Inc.(US), Zap Surgical Systems, Inc.(US), Renishaw Plc (UK)”

North America accounted for the largest share of the medical robots market. As this region is home to a significant number of medical robots manufacturers.

Medical Robots Market in terms of revenue was estimated to be worth $16.0 billion in 2024 and is poised to reach $33.8 billion by 2029, growing at a CAGR of 16.1% from 2024 to 2029 according to a new report by MarketsandMarkets™. The growth in the medical robots market is driven by the aging population and rising chronic diseases, improving reimbursement scenario, and subsequent advancements in healthcare funding & infrastructure. The adoption of medical robots is also expected to increase with the increasing need for automation in healthcare. However, the high cost of robotic systems may pose a challenge to the medical robots market during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2916860

Soft tissue surgical robotic system is the fastest growing in the medical robots market in 2023.

Based on type, the medical robots market is segmented into surgical robotic system, rehabilitation robotic systems, radiosurgery robotic systems, and hospital & pharmacy robotic systems. The surgical robotic systems have been further segmented into surgical robotic systems by application – soft tissue surgical robotic system (general surgery, gynecological surgery, urological surgery, and other applications) and hard tissue surgical robotic system (knee & hip surgery and spine surgery). The rehabilitation robotic systems have been further segmented into rehabilitation robotic systems by type – therapeutic robotic systems, assistive robotic systems, exoskeleton robotic systems, and other rehabilitation robotic systems. The hospital & pharmacy robotic systems have been further segmented into – pharmacy robotic systems (robotic dispensing systems, compounding robotic systems, and other pharmacy robotic systems) and hospital robotic systems (delivery robotic systems, telepresence robotic systems, diagnostic robotic systems, and other hospital robotic systems).

The soft tissue surgical robotic system sub-segment is the fastest growing surgical robotic system in the medical robots market in 2023, attributing to the increasing prevalence of various conditions such as cancer, appendicitis, obesity, and others. These conditions lead to increased demand for robot-assisted surgical procedures with higher accuracy.

Instruments & accessories are the largest product of the medical robots market in 2023.

Based on products & services, the medical robots market is segmented into robotic systems, instruments & accessories, and services. Among these, instruments and accessories segment accounted for the largest share of the medical robots market in 2023. The recurrent purchase of instruments & accessories to be used with the robotic systems instead of robotic systems leads to the higher adoption of this segment.

By end user, ambulatory surgery centers is the fastest growing in the medical robots market in 2023.

Based on end user, the medical robots market is segmented into hospitals & clinics, ambulatory surgery centers, pharmacies, rehabilitation centers, and other end users. The ambulatory surgery centers segment is expected to be the fastest growing segment of the market. The surgical procedures being offered by ASCs at a lower cost than hospitals drives the higher adoption of ambulatory surgery centers among patients.

North America dominates the global medical robots market in 2023.

The medical robots market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. In 2023, North America accounted for the largest share of the medical robots market. As this region is home to a significant number of medical robots manufacturers. Moreover, the increasing adoption of robotic systems by hospitals in the country, the increasing volume of robotic-assisted surgical procedures, and the favourable reimbursement policies in the region, reinforces its position at the forefront of the medical robots market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=2916860

Medical Robots Market Dynamics:

Drivers:

Growing need to minimize medication errors

Restraints:

High cost of robotic systems

Opportunities:

Growth opportunities in emerging markets

Challenge:

Patient and provider acceptance

Key Market Players of Medical Robots Industry:

Prominent players in the medical robots market include Intuitive Surgical, Inc. (US), Stryker Corporation (US), Medtronic Plc (US), Smith & Nephew Plc (UK), Zimmer Biomet Holdings, Inc. (US), Asensus Surgical, Inc.(US), Zap Surgical Systems, Inc.(US), Renishaw Plc (UK), Hocoma Ag (Switzerland), Accuray Incorporated (US), Elekta (Sweden), Becton, Dickinson And Company (US), Omnicell, Inc. (US), Arxium (Canada), Ekso Bionics Holdings, Inc. (US), Bionik Laboratories Corp. (US), Lifeward, Inc. (Israel), Cyberdyne Inc.(Japan), Avateramedical Gmbh (Germany),Johnson & Johnson (US), and Swisslog Healthcare (Switzerland).

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:

By Supply Side: Tier 1 (25%), Tier 2 (5%), and Tier 3 (70%)
By Designation: C-level Executives (27%), Director-level (18%), and Others (55%)
By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East and Africa (5%)

Recent Developments of Medical Robots Industry:

In April 2023, Intuitive Surgical’s da Vinci SP system received US FD for a simple prostatectomy.
In November 2022, an Indian startup SS Innovations launched SSI Mantra for soft tissue surgeries.
In July 2022, Becton, Dickinson & Company (US) acquired Parata Systems (US) to provide portfolio of innovative pharmacy automation solutions to reduce costs, enhance patient safety and improve the patient experience for retail, hospital and long-term care pharmacies.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=2916860

Medical Robots Market – Key Benefits of Buying the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

Analysis of key drivers (aging population and rising chronic diseases, technological advancements, increasing need for automation in healthcare, improving reimbursement scenario, and advancements in healthcare funding & infrastructure, and growing need to minimize medication errors), restraints (high cost of robotic systems and stringent regulatory requirements), opportunities (growth opportunities in emerging markets, and novel application) and challenge (patient and provider acceptance).
Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the medical robots market.
Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of medical robots solutions across regions.
Market Diversification: Exhaustive information about solutions, untapped regions, recent developments, and investments in the medical robots market.
Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the medical robots market.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Robots Market worth $33.8 billion by 2029